Why isn’t one antivenom enough for India? | Explained
India has relied for decades on a single polyvalent antivenom formulated against the venoms of four snake species — Indian cobra, common krait, Russell's viper, and saw-scaled viper — collectively called the "Big Four."
Recent research highlights that this one-size-fits-all approach is scientifically inadequate: venom composition varies significantly not only between species but also within the same species across geographies (intraspecific heterogeneity).
The commercially available Indian polyvalent antivenom shows poor efficacy against medically important snakes found in northeastern India, the Western Ghats, and the Himalayas — including pit vipers, monocled cobras, and the hump-nosed pit viper.
A 2025 study published in ScienceDirect confirmed that the standard polyvalent antivenom fails to neutralize lethality and toxicity from several regionally significant species entirely absent from its formulation.
Experts and researchers are calling for region-specific antivenom formulations and geographically representative venom pools — meaning venom must be extracted from snakes across multiple ecological zones, not just from a narrow population — for antivenom production.
Polyvalent vs. Monovalent Antivenom
Antivenom is produced by immunising horses (equines) with snake venom, collecting the antibodies, and purifying the serum. Polyvalent antivenom targets multiple snake species using a mixed-venom cocktail; monovalent antivenom targets a single species. India's sole commercial polyvalent antivenom uses venom from the Big Four species, all sourced from peninsular India — the geographic source of most commercial snake farms.
Key Details
- Big Four: Indian cobra (Naja naja), common krait (Bungarus caeruleus), Russell's viper (Daboia russelii), saw-scaled viper (Echis carinatus).
- Venom composition varies by geography (intraspecific variation): a Russell's viper from Rajasthan differs biochemically from one in Tamil Nadu or Odisha.
- The antivenom is effective for peninsular India, where the Big Four dominate, but cross-neutralisation is poor for species common elsewhere.
- In northeastern India: monocled cobra and non-caeruleus kraits dominate; in Himachal Pradesh: green pit viper; in Kerala and the Western Ghats: Malabar pit viper and hump-nosed pit viper (Hypnale hypnale).
- India currently has no commercially available antivenom for pit vipers, whose bites are a significant cause of morbidity in the northeast and Western Ghats.
The article's central argument is that a single national antivenom cannot cover India's ecological and herpetological diversity — effective treatment requires region-specific formulations built from geographically diverse venom pools.
Snakebite as a Neglected Tropical Disease
The World Health Organization (WHO) classifies snakebite envenoming as a Priority Neglected Tropical Disease (NTD). It was originally listed in Category A, removed in 2013, and reinstated in 2017 after intense advocacy citing antivenom shortages and rising mortality. In 2019, WHO set a global target to halve snakebite deaths and disabilities by 2030.
Key Details
- India bears the highest snakebite mortality burden globally: approximately 58,000 deaths per year (range: 46,000–81,000 in various studies), representing nearly half of all global snakebite fatalities.
- Globally, snakebite causes approximately 81,000–138,000 deaths annually with 400,000+ cases of permanent disability.
- Snakebite is disproportionately a rural, agricultural community problem — affecting daily-wage farmers, forest workers, and those with no access to referral hospitals.
- India's National Action Plan for Prevention and Control of Snakebite Envenoming (NAPSE), launched in March 2024 by the Union Health Ministry, aims to halve snakebite deaths by 2030 using a One Health approach.
- NAPSE strategy includes: making snakebite a notifiable disease nationwide, establishing Regional Venom Centres, strengthening Poison Information Centres, training health workers, and improving antivenom supply chains.
The policy case for region-specific antivenoms aligns with NAPSE's goal — without reformulating antivenom to cover regionally dominant species, the 2030 mortality-halving target cannot be met in the northeast, Western Ghats, and Himalayan foothills.
Biodiversity and Herpetological Significance
India's herpetofauna (reptile diversity) is exceptionally rich, with over 300 snake species, of which approximately 60 are medically significant. This diversity reflects India's biogeographic position across the Indo-Malayan and Palearctic realms. The Western Ghats and northeastern India are recognised global biodiversity hotspots and harbour significantly different snake assemblages compared to the Deccan plateau or the Indo-Gangetic plain — hence the need for geographically representative antivenom production.
Key Details
- India has ~300 snake species; 60+ are medically significant; only 4 are currently in the national antivenom.
- The Western Ghats is one of 36 global biodiversity hotspots (Conservation International framework).
- Northeastern India (part of the Indo-Burma biodiversity hotspot) has distinct venom profiles requiring separate antivenom formulations.
- "Geographically representative venom pool" means collecting venom from snake populations across multiple ecological zones, not just from captive peninsular populations.
- Intraspecific venom variation is caused by differences in diet, habitat, and evolutionary pressures across geographies.
India's biodiversity — celebrated in conservation policy — is also a medical challenge: a country this ecologically diverse cannot be served by a single antivenom derived from snakes of one geographic region.
- India's snakebite mortality: ~58,000 deaths/year (est. 46,000–81,000 across studies)
- India's share of global snakebite deaths: approximately 50% of all global fatalities
- WHO NTD reinstatement of snakebite: 2017 (removed 2013, reinstated after advocacy)
- WHO 2030 target: Halve snakebite deaths and disability by 2030
- India's NAPSE launch: March 2024; One Health approach
- Big Four snakes: Indian cobra, common krait, Russell's viper, saw-scaled viper
- Current antivenom coverage: Only Big Four (peninsular populations); no pit viper antivenom available commercially
- Hump-nosed pit viper (Hypnale hypnale): Major cause of morbidity in South India — not neutralised by standard polyvalent antivenom
- Total snake species in India: ~300; medically significant: ~60
- Antivenom production method: Hyperimmunisation of equines (horses), followed by antibody purification
- Venom heterogeneity types: Interspecific (between species) and intraspecific (within species, across geographies)